Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Rapino, Daniele ^a   Sabirzhanova, Inna ^a   Lopes Pacheco, Miquéias ^a   Grover, Rahul ^a   Guggino, William B ^a   Cebotaru, Liudmila ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MOLECULAR THERAPY AGENT; MUTANT PROTEIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PROTEASOME; SMALL MOLECULE CORRECTOR; TUBACIN; UNCLASSIFIED DRUG; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; MOLECULAR LIBRARY; PROTEIN BINDING;

AGGRESOME; ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CFTR GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; GENE; GENE MUTATION; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; NBD2 GENE; NONHUMAN; PLASMID; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; TEMPERATURE SENSITIVITY; TRANSCOMPLEMENTATION; ANIMAL; CHLOROCEBUS AETHIOPS; COS CELL LINE; CYSTIC FIBROSIS; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR LIBRARY; MUTATION; PATHOLOGY; PHARMACOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CERCOPITHECUS AETHIOPS; COS CELLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC COMPLEMENTATION TEST; HEK293 CELLS; HUMANS; MUTATION; PROTEIN BINDING; SMALL MOLECULE LIBRARIES;

EID: 84925778077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119796     Document Type: Article

References (46)

1. Fuller CM, Benos DJ CFTR! Am J Physiol. 1992; 263: C267-C286. PMID: 1381146
2. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (delta F508). N Engl J Med. 1990; 323: 1517-1522. PMID: 2233932
3. Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grezelczak Z, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073. PMID: 2475911
4. Mendoza JL, Schmidt A, Li Q, Nuvaga E, Barrett T, Bridges RJ, Feranchak AP, et al. Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 2012; 148: 164-174. S0092-8674(11)01367-5. doi: 10.1016/j.cell.2011.11.023 PMID: 22265409
5. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-764. PMID: 1380673
6. Loo MA, Jensen TJ, Cui L, Hou Y, Chang XB, Riordan JR Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J. 1998; 17: 6879-6887. PMID: 9843494
7. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363: 1991-2003. doi: 10.1056/NEJMoa0909825 PMID: 21083385
8. Fulmer SB, Schwiebert EM, Morales MM, Guggino WB, Cutting GR Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. Proc Natl Acad Sci U S A. 1995; 92: 6832-6836. PMID: 7542778
9. Van GF, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009; 106: 18825-18830. doi: 10.1073/pnas.0904709106 PMID: 19846789
10. Van GF, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011; 108: 18843-18848. doi: 10.1073/pnas.1105787108 PMID: 21976485
11. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012; 67: 12-18. doi: 10.1136/thoraxjnl-2011-200393 PMID: 21825083
12. Cebotaru L, Rapino D, Cebotaru V, GugginoWB Correcting the cystic fibrosis disease mutant, A455E CFTR. PLoS One 2014; 9: e85183. doi: 10.1371/journal.pone.0085183 PMID: 24416359
13. Csanady L, Vergani P, Gadsby DC Strict coupling between CFTR's catalytic cycle and gating of its Clion pore revealed by distributions of open channel burst durations. Proc Natl Acad Sci U S A. 2010; 107: 1241-1246. doi: 10.1073/pnas.0911061107 PMID: 19966305
14. Thibodeau PH, Richardson JM III, Wang W, Millen L, Watson J, Mendoza JL, et al. The cystic fibrosiscausing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 2010; 285: 35825-35835. doi: 10.1074/jbc.M110.131623 PMID: 20667826
15. Kleizen B, van VT, De Jonge HR, Braakman I Folding of CFTR is predominantly cotranslational. Mol Cell 2005; 20: 277-287. S1097-2765(05)01607-2 PMID: 16246729
16. Lu Y, Xiong X, Helm A, Kimani K, Bragin A, Skach WR Co-and posttransltional translocation mechanisms direct cystic fibrosis transmembrane conductance regulator N terminus transmembrane assembly. J Biol Chem 1998; 273: 568-576. PMID: 9417117
17. Federici S, Iron A, Reboul MP, Desgeorges M, Claustres M, Bremont F, et al. [CFTR gene analyis in 207 patients with cystic fibrosis in southwest France: high frequency of N1303K and 1811+1.6bA>G mutations]. Arch Pediatr 8: 150-157. PMID: 11232455
18. Cotellessa M, Mazzella M, Bruno C, Buzzanca C, Minicucci L, Gandino M, et al. N1303K mutation and diabetes mellitus in cystic fibrosis. Arch Dis Child 1996; 75: 546. PMID: 9014614
19. Ataseven F, Ozer S, Yilmaz R, Senayli A (2010) Bilateral spontaneous pneumothorax in a newborn with N1303K mutation of cystic fibrosis (CFTR) gene. Tuberk Toraks 58: 181-183. PMID: 20865572
20. Castellani C, Gomez LM, Frulloni L, Delmarco A, Marzari M, Bonizzato A, et al. Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in idiopathic pancreatitis. Hum Mutat. 2001; 18: 166. PMID: 11462247
21. Auriche C, Di Domenico EG, Pierandrei S, Lucarelli M, Castellani S, Conese M, et al. CFTR expression and activity from the human CFTR locus in BAC vectors, with regulatory regions, isolated by a singlestep procedure. Gene Ther 2010; 17: 1341-1354. doi: 10.1038/gt.2010.89 PMID: 20535216
22. Reboul MP, Laharie D, Amouretti M, Lacombe D, Iron A Isolated idiopathic chronic pancreatitis associated with a compound heterozygosity for two mutations of the CFTR gene. Gastroenterol Clin Biol 2003; 27: 821-824. PMID: 14586256
23. Feldmann D, Couderc R, Audrezet MP, Ferec C, Bienvenu T, Desgeorges M, et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat 2003; 22: 340. PMID: 12955727
24. Van GF, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-L1130. PMID: 16443646
25. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-2571. PMID: 16127463
26. Holleran JP, Glover ML, Peters KW, Bertrand CA, Watkins SC, Jarvik JW, et al. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol Med 2012; 18: 685-696. doi: 10.2119/molmed.2012.00001 PMID: 22396015
27. Cebotaru L, Woodward O, Cebotaru V, Guggino WB Transcomplementation by a truncation mutant of CFTR enhances ΔF508 processing through a biomolecular interaction. J Biol Chem. 2013; M112.420489.
28. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr., et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167. PMID: 12413414
29. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-1658. PMID: 12464670
30. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003; 100: 4389-4394. PMID: 12677000
31. Barrett AJ, Kembhavi AA, Hanada K E-64 [L-trans-epoxysuccinyl-leucyl-amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases. Acta Biol Med Ger 40: 1981;1513-1517. PMID: 7044005
32. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738. PMID: 14675537
33. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, et al. Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 2013; 9: 444-454. doi: 10.1038/nchembio.1253 PMID: 23666117
34. Obrig TG, Culp WJ, McKeehan WL, Hardesty B The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem. 1971; 246: 174-181. PMID: 5541758
35. Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR, et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem. 1993; 268: 21592-21598. PMID: 7691813
36. Heda GD, Tanwani M, Marino CR (2001) The DeltaF508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 280: C166-C174. PMID: 11121388
37. Amaral MD CFTR and chaperones: processing and degradation. J Mol Neurosci 2004; 23: 41-48. PMID: 15126691
38. Choo-Kang LR, Zeitlin PL Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol. 2001; 281: L58-L68. PMID: 11404246
39. Yang Y, Janich S, Cohn JA, Wilson JM The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A 1993; 90: 9480-9484. PMID: 7692448
40. Li J, Qian X, Sha B Heat shock protein 40: structural studies and their functional implications. Protein Pept Lett 2009; 16: 606-612. PMID: 19519518
41. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W, et al. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357-3366. PMID: 16810319
42. Cebotaru L, Vij N, Ciobanu I, Wright J, Flotte T, Guggino WB Cystic fibrosis transmembrane regulator missing the first four transmembrane segments increases wild type and DeltaF508 processing. J Biol Chem. 2008; 283: 21926-21933. doi: 10.1074/jbc.M709156200 PMID: 18508776
43. Sosnay PR, Siklosi KR, Van GF, Kaniecki K, Yu H, Sharma N, Ramalho AS, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; 45: 1160-1167. doi: 10.1038/ng.2745 PMID: 23974870
44. Lewis HA, Buchanan SG, Burley SK, Conners K, Dickey M, Dorwart M, et al. Structure of nucleotidebinding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 2004; 23: 282-293. PMID: 14685259
45. Du K, Sharma M, Lukacs GL The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol. 2005; 12: 17-25. PMID: 15619635
46. Osborne L, Santis G, Schwarz M, Klinger K, Dork T, McIntosh I, et al. Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene. Hum Genet. 1992; 89: 653-658. PMID: 1380943